Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JT001 (VV116) for Early Treatment of Mild to Moderate COVID-19
NCT05242042Phase 3Terminated
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Jan 2022
- Primary completion
- Mar 2023
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing JT001 (VV116) with Placebo (2 arms). Primary endpoint: Progression of COVID-19 to severe/critical or death at 28 days. Started Jan 2022; status: terminated.
02
Drugs
deuremidevir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05242042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05242042.